RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. These therapies are currently being developed using different types of RNA-based molecules, including coding RNAs (such as mRNA) and non-coding RNAs (such as interfering RNAs (RNAi), antisense oligonucleotides (ASO) and RNA aptamers). The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. However, despite the potential benefits offered by this therapeutic modality, the unique challenges associated with drug delivery, manufacturing, logistics and storage led to a decline in the popularity of RNA therapies post the initial rise in early 2000s. Consequently, some activity in this domain was reported in 2018, when ONPATTRO (developed by Alnylam Pharmaceuticals) received approval from USFDA and EMA; this RNAi therapy was intended for the treatment of hereditary transthyretin amyloidosis (hATTR), a rare and life-threatening disorder. Subsequently, it was the phenomenal success of mRNA therapies against the COVID-19 pandemic which fully reignited the interest of general public, patients, healthcare providers and investors in this market. For instance, in 2021 and 2022, two mRNA vaccines intended for COVID-19 received emergency use approvals from the USFDA; these were BNT162b2 (developed by BioNTech and Pfizer) and mRNA-1273 (developed by Moderna). In addition, RNA therapeutics have shown promising results in the treatment of rare diseases, particularly neurological and hepatic diseases. In fact, 80% of such therapies being evaluated in late stages of clinical development have received the orphan drug designation. This further showcases the potential of RNA therapeutics to actualize the concept of personalized medicine in the foreseen future.
RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein function and broaden the range of druggable targets, thereby, paving way for new avenues in disease diagnosis and treatment. Foreseeing these opportunities, numerous start-ups have been established in the last few years, indicating the growing interest in this sector. Owing to the rising demand for better therapeutic options and increasing adoption rate of such therapies, the investment focus for RNA therapeutics has increased significantly. In fact, since 2011, a total of over USD 16 billion was raised by RNA-based drug developers to advance their pipeline candidates. It is worth highlighting that, amongst the RNA therapeutics investors, majority of the investments have been led by mRNA vaccines investors and mRNA therapeutics investors. This is followed by RNAi therapeutics investors and RNA aptamers investors. Driven by the rise in government initiatives for early commercialization of pipeline therapeutics and active involvement of RNA therapeutics investors, we anticipate a variety of novel RNA based therapeutics to be developed, presenting lucrative investment opportunities for both short- and long-term investors.
Scope of the Report
The Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity and Company Valuation, Financial Analysis and Business Risk Assessment of Key Public Ventures, Market Forecast and Opportunity Analysis, Analysis of Returns on Investment, Key Acquisition Targets) report provides detailed information on the RNA therapeutics market, covering the various types of RNA therapeutics, including RNAi therapies, RNA aptamers, and mRNA therapies and mRNA vaccines. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, till 2035. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:
- An introduction to RNA therapeutics, highlighting information on products that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of RNA therapies, and the opinions of representatives from key stakeholder companies involved in this domain.
- A detailed analysis of RNA therapeutics focused companies that were established post-2007, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size and type of venture.
- An assessment of the various products, offered by innovator companies engaged in this domain, based on number of products and type of product. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on basic company details, product portfolio, financing activity, estimated revenues and profits) of different innovator companies, using a proprietary scoring criterion, which was informed via secondary research.
- An informed perspective on the value proposition of companies captured in the report based on multiple relevant aspects, namely therapy-related aspect, developer-related aspect, technology-related aspect, and patient-related aspect.
- A company competitiveness analysis, highlighting a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of RNA therapeutics. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
- A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of innovator companies mentioned in the report. Further, it features a list of leading investors in RNA therapeutics market, based on their participation in financing activity in this industry segment.
- A proprietary analysis defining a basis for estimating the relative valuation of private companies, among the innovators discussed in this report. The value statements generated under this analytical framework were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated to generate the likely valuation estimates for all companies in the dataset.
- An elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
- Elaborate profiles of the prominent public ventures engaged in the development of RNA therapeutics, featuring a brief overview of the company, details on its management team, insights generated from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).
- A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).
- A detailed market forecast analysis, highlighting the likely evolution of the RNA therapeutics market in the short to mid-term and long term, over the period 2023-2035. Further the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
- A case study where investors have exited various RNA therapeutics-related ventures, offering insights on returns on investment received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
- A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- What are the key advantages offered by RNA therapies and vaccines?
- Which drugs are being evaluated across early and late stages of pipeline?
- Which are the key therapeutic areas targeted by RNA therapeutics
- What type of therapies that are being offered by the innovator companies?
- What are the key value propositions offered by players engaged in the RNA therapeutics domain?
- What is the relative competitiveness of different players engaged in the development of RNA therapeutics?
- Who are the key investors that are actively supporting the development and commercialization of RNA therapeutics?
- What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape?
- Who are the potential acquisition targets for investors in the RNA therapeutics domain?
- What are the major risks for investors seeking to tap into the RNA therapeutics domain?
- What is the estimated return on investments received by the investors?
- How is the current and future market opportunity related to RNA therapeutics likely to be distributed across key market segments?
Table of Contents
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovators Landscape
1.3. Products Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in RNA Therapeutics
2.4 Appendices
3. COMPANY VALUATION ANALYSIS
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
3.4. Appendices
4. FUNDAMENTAL FINANCIAL ANALYSIS
4.1. Analysis Notes
4.2. Summary Dashboard
4.3. Company Fundamentals
4.4. Fundamental Analysis
4.4.1. Financial Ratios
4.4.4.1. Liquidity Ratios
4.4.4.2. Financial and Business Risk Ratios
4.4.4.3. Turnover / Efficiency Ratios
4.4.4.4. Profitability Ratios
4.4.4.4. Market Value Ratios
4.4.4.5. Stability Ratios
4.5. Appendices
5. TECHNICAL FINANCIAL ANALYSIS
5.1. Analysis Notes
5.2. Key Highlights
5.3. Open High Low Close Chart / Stock Price & Volume Traded (Last 100 Days)
5.4. 5 Day Moving Average (Buy & Sell Signals)
5.5. 10 Day Moving Average (Buy & Sell Signals)
5.6. 50 Day Moving Average (Buy & Sell Signals)
5.7. Bollinger Bands®
5.8. Relative Strength Index
5.9. Average Directional Index
5.10. Commodity Channel Index
5.11. Williams R
5.12. Moving Average Convergence Divergence (MACD)
5.13. Appendices
6. BUSINESS RISK ASSESSMENT
6.1. Analysis Notes
6.2. Business Risk Data
6.3. Appendices
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Analysis Notes
7.2. Market Forecast and Opportunity Analysis: Summary
7.3. Market Forecast and Opportunity Analysis: Base Scenario
7.4. Market Forecast and Opportunity Analysis: Conservative Scenario
7.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
8. ANALYSIS OF RETURNS ON INVESTMENT
8.1. Analysis Notes
8.2. Estimated RoI for Investors in Company A
8.3. Estimated RoI for Investors in Company B
8.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Introduction to RNA Therapeutics and Innovators Landscape
5. THE RNA THERAPEUTICS MARKET
5.1. Overview
5.2. Types of RNA Therapeutics
5.3. Historical Development
5.4. Applications of RNA Therapeutics
5.5. Benefits of RNA Therapeutics
5.6. Challenges Associated with RNA Therapeutics
5.7. Contemporary Sentiments and Expert Opinions
6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE
6.1. Methodology
6.2. Innovators in the RNA Therapeutics Market
6.3. Analysis of Innovators Landscape
6.4. Concluding Remarks
7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of RNA Therapeutics
7.2. Analysis of Products Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Value Proposition Analysis: Therapy-related Aspect
8.3. Value Proposition Analysis: Developer-related Aspect
8.4. Value Proposition Analysis: Technology-related Aspect
8.5. Value Proposition Analysis: Patient-related Aspect
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks
Section II: Analysis of Investments and Company Valuation
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. Funding and Investments Summary
11. COMPANY VALUATION ANALYSIS
11.1. Overview and Methodology
11.2. Valuation of Public Companies
11.3. Company Valuation: Based on Company Size
11.4. Company Valuation: Based on Latest Stage of Financing
11.5. Company Valuation: Based on Company Size and Latest Stage of Funding
Section III: Financial Analysis and Assessment of Business Risks
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.2. Financial Ratios (Interpretation Guide)
12.3. Fundamental Financial Analysis: List of Public Companies
12.4. Case Study 1
12.5. Technical Financial Analysis Overview
12.6. Technical Indicators (Interpretation Guide)
12.7. Technical Financial Analysis: List of Public Companies
12.8. Case Study 2
13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Arbutus Biopharma
13.1.1. Key Highlights
13.1.1.1. Company Overview
13.1.1.2. Insights from Balance Sheet
13.1.1.3. Key Executive Team
13.1.1.4. Recent Developments
13.1.2. Key Financial Details
13.1.2.1. Company Investments
13.1.2.2. Company Fundamentals
13.1.2.3. Company Technicals
13.2. Arcturus Therapeutics
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Insights from Balance Sheet
13.2.1.3. Key Executive Team
13.2.1.4. Recent Developments
13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals
13.3. GreenLight Biosciences
13.3.1. Key Highlights
13.3.1.1. Company Overview
13.3.1.2. Insights from Balance Sheet
13.3.1.3. Key Executive Team
13.3.1.4. Recent Developments
13.3.2. Key Financial Details
13.3.2.1. Company Investments
13.3.2.2. Company Fundamentals
13.3.2.3. Company Technicals
13.4. Gritstone bio
13.4.1. Key Highlights
13.4.1.1. Company Overview
13.4.1.2. Insights from Balance Sheet
13.4.1.3. Key Executive Team
13.4.1.4. Recent Developments
13.4.2. Key Financial Details
13.4.2.1. Company Investments
13.4.2.2. Company Fundamentals
13.4.2.3. Company Technicals
13.5. IVERIC bio
13.5.1. Key Highlights
13.5.1.1. Company Overview
13.5.1.2. Insights from Balance Sheet
13.5.1.3. Key Executive Team
13.5.1.4. Recent Developments
13.5.2. Key Financial Details
13.5.2.1. Company Investments
13.5.2.2. Company Fundamentals
13.5.2.3. Company Technicals
13.6. Moderna
13.6.1. Key Highlights
13.6.1.1. Company Overview
13.6.1.2. Insights from Balance Sheet
13.6.1.3. Key Executive Team
13.6.1.4. Recent Developments
13.6.2. Key Financial Details
13.6.2.1. Company Investments
13.6.2.2. Company Fundamentals
13.6.2.3. Company Technicals
13.7. Omega Therapeutics
13.7.1. Key Highlights
13.7.1.1. Company Overview
13.7.1.2. Insights from Balance Sheet
13.7.1.3. Key Executive Team
13.7.1.4. Recent Developments
13.7.2. Key Financial Details
13.7.2.1. Company Investments
13.7.2.2. Company Fundamentals
13.7.2.3. Company Technicals
13.8. Phio Pharmaceuticals
13.8.1. Key Highlights
13.8.1.1. Company Overview
13.8.1.2. Insights from Balance Sheet
13.8.1.3. Key Executive Team
13.8.1.4. Recent Developments
13.8.2. Key Financial Details
13.8.2.1. Company Investments
13.8.2.2. Company Fundamentals
13.8.2.3. Company Technicals
13.9. Regulus Therapeutics
13.9.1. Key Highlights
13.9.1.1. Company Overview
13.9.1.2. Insights from Balance Sheet
13.9.1.3. Key Executive Team
13.9.1.4. Recent Developments
13.9.2. Key Financial Details
13.9.2.1. Company Investments
13.9.2.2. Company Fundamentals
13.9.2.3. Company Technicals
13.10. Vir Biotechnology
13.10.1. Key Highlights
13.10.1.1. Company Overview
13.10.1.2. Insights from Balance Sheet
13.10.1.3. Key Executive Team
13.10.1.4. Recent Developments
13.10.2. Key Financial Details
13.10.2.1. Company Investments
13.10.2.2. Company Fundamentals
13.10.2.3. Company Technicals
14. BUSINESS RISK ASSESSMENT
14.1. Overview and Methodology
14.2. Operations-related Risks
14.3. Business-related Risks
14.4. Financial / Asset-related Risks
14.5. Product / Technology-related Risks
14.6. Industry Specific Risks
14.7. Other Risks
14.8. Summary of Business Risk Assessment
Section IV: Market Forecast and Opportunity Analysis
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Overview and Methodology
15.2. Global RNA Therapeutics Market, 2023-2035
15.2.1. RNA Therapeutics Market: Analysis by Type of Therapy, 2023 and 2035
15.2.1.1. RNA Therapeutics Market for miRNA Therapies, 2023-2035
15.2.1.2. RNA Therapeutics Market for siRNA Therapies, 2023-2035
15.2.1.3. RNA Therapeutics Market for mRNA Therapies, 2023-2035
15.2.1.4. RNA Therapeutics Market for mRNA Vaccines, 2023-2035
15.2.1.5. RNA Therapeutics Market for RNA Aptamers, 2023-2035
15.2.2. RNA Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
15.2.2.1. RNA Therapeutics Market for Infectious Diseases, 2023-2035
15.2.2.2. RNA Therapeutics Market for Metabolic Disorders, 2023-2035
15.2.2.3. RNA Therapeutics Market for Oncological Disorders, 2023-2035
15.2.2.4. RNA Therapeutics Market for Genetic Disorders, 2023-2035
15.2.2.5. RNA Therapeutics Market for Other Disorders, 2023-2035
15.2.3. RNA Therapeutics Market: Analysis by Route of Administration, 2023 and 2035
15.2.3.1. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035
15.2.3.2. RNA Therapeutics Market for Intravenous Therapies, 2023-2035
15.2.3.3 RNA Therapeutics Market for Intranasal Therapies, 2023-2035
15.2.3.4 RNA Therapeutics Market for Other Routes of Administration, 2023-2035
15.2.4. RNA Therapeutics Market: Analysis by Key Geographies, 2023 and 2035
15.2.4.1. RNA Therapeutics Market in North America, 2023-2035
15.2.4.2. RNA Therapeutics Market in Europe, 2023-2035
15.2.4.3. RNA Therapeutics Market in Asia, 2023-2035
15.2.4.3. RNA Therapeutics Market in Latin America, 2023-2035
15.2.4.3. RNA Therapeutics Market in Middle East and North Africa, 2023-2035
15.2.4.3. RNA Therapeutics Market in Rest of the World, 2023-2035
Section V: Analysis of Returns on Investment and Key Acquisition Targets
16. ANALYSIS OF RETURNS ON INVESTMENT
16.1. Overview and Methodology
16.2. Case Studies
16.2.1. Avidity Biosciences
16.2.2. BioNTech
16.2.3. GreenLight Biosciences
16.2.4. Gritstone bio
16.2.5. IVERIC bio
16.2.6. Moderna
16.2.7. Regulus Therapeutics
16.2.8. Vir Biotechnology
16.3. Concluding Remarks
17. KEY ACQUISITION TARGETS
17.1. Overview
17.2. List of Key Acquisition Targets
17.3. Concluding Remarks
18. CONCLUSION
19. APPENDICES
List Of Figures
Figure 5.1. RNA Therapeutics: Key Definitions and Background
Figure 5.2. RNA Therapeutics: Types of Therapies and Key Industry Players
Figure 5.3. RNA Therapeutics: Key Historical Developments
Figure 5.4. RNA Therapeutics: Key Strategic Initiatives of Industry Players
Figure 5.5. RNA Therapeutics: Key Marketed Products and Current Unmet Needs
Figure 6.1. Innovators Landscape: Distribution by Year of Establishment
Figure 6.2. Innovators Landscape: Distribution by Type of Venture
Figure 6.3. Innovators Landscape: Distribution by Company Size
Figure 6.4. Innovators Landscape: Distribution by Geography
Figure 7.1. Products Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Products Landscape: Distribution by Type of Products
Figure 7.3. Products Landscape: Distribution of Products by Phase of Development
Figure 7.4. Products Landscape: Distribution of Products by Route of Administration
Figure 7.5. Products Landscape: Distribution of Products by Therapeutic Area
Figure 8.1. Therapy-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.2. Therapy-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.3. Developer-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.4. Developer-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.5. Technology-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.6. Technology-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.7. Patient-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.8. Patient-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.9. Summary of Value Proposition Analysis
Figure 9.1. Competitiveness Analysis: Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Companies based in Europe (Peer Group II)
Figure 9.3. Competitiveness Analysis: Companies based in Asia and Rest of the World (Peer Group III)
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, 2011-2022
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Distribution of Instances and Amount Invested by Region
Figure 10.5. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 10.6. Funding and Investment Analysis: Most Active Players by Amount Raised
Figure 10.7. Awards / Grants: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Distribution of Amount Invested by Region
Figure 10.9. Awards / Grants: Most Active Investors by Amount Invested
Figure 10.10. Seed Funding: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Distribution of Amount Invested by Region
Figure 10.12. Seed Funding: Most Active Investors by Amount Invested
Figure 10.13. Venture (Series A): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.14. Venture (Series A): Distribution of Amount Invested by Region
Figure 10.15. Venture (Series A): Most Active Investors by Amount Invested
Figure 10.16. Venture (Series B): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.17. Venture (Series B): Distribution of Amount Invested by Region
Figure 10.18. Venture (Series B): Most Active Investors by Amount Invested
Figure 10.19. Venture (Series C): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series C): Distribution of Amount Invested by Region
Figure 10.21. Venture (Series C): Most Active Investors by Amount Invested
Figure 10.22. Venture (Series D, E, F, G, H, and Unknown) Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series D, E, F, G, H, and Unknown): Distribution of Amount Invested by Region
Figure 10.24. Venture (Series D, E, F, G, H, and Unknown): Most Active Investors by Amount Invested
Figure 10.25. Public Offerings: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.26. Public Offerings: Distribution of Amount Invested by Region
Figure 10.27. Public Offerings: Publicly Listed Players
Figure 10.28. Private Placements: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.29. Private Placements: Distribution of Amount Invested by Region
Figure 10.30. Private Placements: Most Active Investors by Amount Invested
Figure 10.31. Debt Financing: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.32. Debt Financing: Distribution of Amount Invested by Region
Figure 10.33. Debt Financing: Most Active Investors by Amount Invested
Figure 10.34. Capital Investments in RNA Therapeutics: Summary of Investments, 2011-2022
Figure 12.1. Arbutus Biopharma: Annual Revenues and Key Balance Sheet Parameter-related Trends, 2017-2022
Figure 12.2. Arbutus Biopharma: Liquidity Ratios, 2017-2022
Figure 12.3. Arbutus Biopharma: Financial and Business Risk Ratios and Turnover / Efficiency Ratios, 2017-2022
Figure 12.4. Arbutus Biopharma: Profitability Ratios, 2017-2022
Figure 12.5. Arbutus Biopharma: Market Value Ratios and Stability Ratios, 2017-2022
Figure 12.6. Arcturus Therapeutics: Stock Price (Candlestick Chart) and Volume Traded
Figure 12.7. Arcturus Therapeutics: 5-Day Moving Average
Figure 12.8. Arcturus Therapeutics: 10-Day Moving Average
Figure 12.9. Arcturus Therapeutics: 50-Day Moving Average
Figure 12.10. Arcturus Therapeutics: Bollinger Band
Figure 12.11. Arcturus Therapeutics: Relative Strength Index
Figure 12.12. Arcturus Therapeutics: Commodity Channel Index (CCI)
Figure 12.13. Arcturus Therapeutics: Moving Average Convergence / Divergence (MACD)
Figure 12.14. Arcturus Therapeutics: Williams’ R Analysis
Figure 12.15. Arcturus Therapeutics: Average Directional Index (ADX)
Figure 13.1. Arbutus Biopharma: Company Fundamentals
Figure 13.2. Arbutus Biopharma: Trend of Stock Prices Since Initial Public Offering
Figure 13.3. Arcturus Therapeutics: Company Fundamentals
Figure 13.4. Arcturus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.5. GreenLight Biosciences: Company Fundamentals
Figure 13.6. GreenLight Biosciences: Trend of Stock Prices Since Initial Public Offering
Figure 13.7. Gritstone bio: Company Fundamentals
Figure 13.8. Gritstone bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.9. IVERIC bio: Company Fundamentals
Figure 13.10. IVERIC bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.11. Moderna: Company Fundamentals
Figure 13.12. Moderna: Trend of Stock Prices Since Initial Public Offering
Figure 13.13. Omega Therapeutics: Company Fundamentals
Figure 13.14. Omega Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.15. Phio Pharmaceuticals: Company Fundamentals
Figure 13.16. Phio Pharmaceuticals: Trend of Stock Prices Since Initial Public Offering
Figure 13.17. Regulus Therapeutics: Company Fundamentals
Figure 13.18. Regulus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.19. Vir Biotechnology: Company Fundamentals
Figure 13.20. Vir Biotechnology: Trend of Stock Prices Since Initial Public Offering
Figure 14.1. Business Risk Assessment: Operations-related Risks
Figure 14.2. Business Risk Assessment: Business-related Risks
Figure 14.3. Business Risk Assessment: Financial / Asset-related Risks
Figure 14.4. Business Risk Assessment: Product / Technology-related Risks
Figure 14.5. Business Risk Assessment: Industry Specific Risks
Figure 14.6. Business Risk Assessment: Other Risks
Figure 14.7. Summary of Business Risk Assessment
Figure 15.1. RNA Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 15.2. RNA Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 15.3. RNA Therapeutics Market for miRNA Therapies, 2023-2035 (USD Million)
Figure 15.4. RNA Therapeutics Market for siRNA Therapies, 2023-2035 (USD Million)
Figure 15.5 RNA Therapeutics Market for mRNA Therapies, 2023-2035 (USD Million)
Figure 15.6. RNA Therapeutics Market for mRNA Vaccines, 2023-2035 (USD Million)
Figure 15.7. RNA Therapeutics Market for RNA Aptamers, 2023-2035 (USD Million)
Figure 15.8. RNA Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 15.9. RNA Therapeutics Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 15.10. RNA Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 15.11. RNA Therapeutics Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 15.12. RNA Therapeutics Market for Genetic Disorders, 2023-2035 (USD Million)
Figure 15.13. RNA Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 15.14. RNA Therapeutics Market: Distribution by Route of Administration, 2023 and 2035
Figure 15.15. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035 (USD Million)
Figure 15.16. RNA Therapeutics Market for Intravenous Therapies, 2023-2035 (USD Million)
Figure 15.17. RNA Therapeutics Market for Intranasal Therapies, 2023-2035 (USD Million)
Figure 15.18. RNA Therapeutics Market for Other Routes of Administration, 2023-2035 (USD Million)
Figure 15.19. RNA Therapeutics Market: Distribution by Key Geographies, 2023 and 2035
Figure 15.20. RNA Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 15.21. RNA Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 15.22. RNA Therapeutics Market in Asia, 2023-2035 (USD Million)
Figure 15.23. RNA Therapeutics Market in Latin America, 2023-2035 (USD Million)
Figure 15.24. RNA Therapeutics Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.25. RNA Therapeutics Market in Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Avidity Biosciences: Returns on Investment Reported by Selected Stakeholdersand Historical Funding Activity
Figure 16.2. BioNTech: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.3. GreenLight Biosciences: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.4. Gritstone bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.5. IVERIC bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.6. Moderna: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.7. Regulus Therapeutics: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.8. Vir Biotechnology: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 17.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 17.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (I/IV)
Figure 17.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (II/IV)
Figure 17.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (III/IV)
Figure 17.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (IV/IV)
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia and Rest of the World
List Of Tables
Table 6.1. Key Innovators in the RNA Therapeutics Market
Table 7.1. Products Offered by Innovators in the RNA Therapeutics Market
Table 7.2. RNA Therapeutics Developers: Company Health Indexing (I/V)
Table 7.3. RNA Therapeutics Developers: Company Health Indexing (II/V)
Table 7.4. RNA Therapeutics Developers: Company Health Indexing (III/V)
Table 7.5. RNA Therapeutics Developers: Company Health Indexing (IV/V)
Table 7.6. RNA Therapeutics Developers: Company Health Indexing (V/V)
Table 11.1. Valuation of Public Companies: Sample Dataset
Table 11.2. Company Valuation: Based on Company Size
Table 11.3. Company Valuation: Based on Latest Stage of Financing
Table 11.4. Company Valuation: Based on Company Size and Latest Stage of Funding
Table 12.1. Fundamental Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 12.2. Technical Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 17.1. RNA Therapeutics Developers: Likely Acquisition Targets (Company Strength)
Table 17.2. RNA Therapeutics Developers: Likely Acquisition Targets (Value Proposition)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 8VC
- Abu Dhabi Investment Authority (ADIA)
- ACM Biolabs
- Advantech Capital
- AIM Vaccine
- Alethea Capital Management
- Alexandria Venture Investments
- Alexion Pharmaceuticals
- Ally Bridge Group
- Alnylam Pharmaceuticals
- Alta Partners
- Amgen Ventures
- aptaTargets
- Arbutus Biopharma
- ARCH Venture Partners
- Arcturus Therapeutics
- ARIZ Precision Medicine
- ArrowMark Partners
- Ascletis Pharma
- AstraZeneca
- AT Impf
- Atlanta Therapeutics
- Atlas Venture
- Avidity Biosciences
- AyurMaya Capital Management
- Bain Capital Life Sciences
- Baird Capital
- Basking Biosciences
- BB Biotech Ventures
- Bill & Melinda Gates
- Bio-Matrix Scientific (BMSN)
- BioAxone BioSciences
- Biogen
- Biomedical Advanced Research and Development Authority (BARDA)
- BioNTech
- BIORCHESTRA
- BlueIO
- Boehringer Ingelheim Venture Fund
- Brace Pharma Capital
- Broadview Ventures
- Brookside Capital
- Builders Vision
- Caixa Capital Risc
- CanSino Biologics
- Casdin Capital
- CBC Group
- CDH Investments
- Centre for the Development of Industrial Technology (CDTI)
- Chimeron Bio
- China Growth Capital
- China Venture Capital
- Chong Kun Dang Pharmaceutical
- Clarus Life Sciences
- Colt Ventures
- Company K Partners
- Cormorant Asset Management
- Cowen
- CPE Yuanfeng Investments
- CR-CP Life Science Fund
- CureDuchenne
- Cystic Fibrosis Foundation
- Daily Partners
- Defense Advanced Research Projects Agency (DARPA)
- Dicerna Pharmaceuticals
- Domain Associates
- EcoR1 Capital
- EIT Health
- Eli Lilly
- EQT Life Sciences
- eTheRNA
- Ethris
- European Investment Bank
- European Union
- ExploRNA Therapeutics
- Fall Line Endurance
- Federated Hermes
- Fidelity Investments
- Flagship Pioneering
- Flanders Innovation & Entrepreneurship (VLAIO)
- Fortune Capital
- F-Prime Capital
- Frazier Healthcare Partners
- Fund+
- Future Industry Investment Fund
- Genmab
- German Federal Ministry of Education and Research
- GGV Capital
- Gilead Sciences
- GL Ventures
- Global Source Ventures
- Goldman Sachs
- GoldStone Investment
- GreenLight Biosciences
- Gritstone bio
- GSK
- Guangzhou Sino-Israel Biotechnology Fund (GIBF)
- Guardian Therapeutics
- HBM Healthcare Investments
- Hercules Capital
- High-Tech Gründerfonds (HTGF)
- Hummingbird Ventures
- IMM Investment
- Immorna
- InnoRNA
- Innosuisse
- Innovate UK
- Insud Pharma
- Inveready
- Invus
- Ionis Pharmaceuticals
- IVERIC bio
- JAFCO
- Janus Henderson Investors
- Julius Baer
- KB Investment
- Kernal Biologics
- Kiwoom Investment
- Kodiak Venture Partners
- Laureus Capital
- Leaps by Bayer
- LeBow Alpha
- Legend Capital
- Legend Star
- Lilly Asia Ventures
- Lincoln Park Capital
- Logos Capital
- Longmen Capital
- MassChallenge
- Medine
- MedLab Clinical
- Merck
- Mercurna
- MIG Material Innovative
- Ministry of Economy and Competitiveness
- Mirae Asset Capital
- miReven
- MLS Capital Fund II
- Moderna
- Moneta Ventures
- MOORE VENTURE PARTNERS
- Morningside VenturesSS
- MP Healthcare Venture Management
- MPM Capital
- Myeloid Therapeutics
- NanoDe Therapeutics
- National Center for Advancing Translational Sciences
- National Institute of Health (NIH)
- New Enterprise Associates (NEA)
- Novalis LifeSciences
- Novo Holdings
- OliX Pharmaceuticals
- Omega Fund
- Omega Therapeutics
- OrbiMed
- Oxford Bioscience Partners
- Oxford Finance
- Panlin Capital
- Pantherna Therapeutics
- Partner Fund Management
- Pavilion Capital
- Perceptive Advisors
- Pfizer
- Phio Pharmaceuticals (previously Rxi Pharmaceuticals)
- pHion Therapeutics
- Pictet
- PMV
- Point72
- Providence Therapeutics
- QianHai FOF
- Qianhai Fund of Funds
- Qiming Venture Partners
- RA Capital
- ReCode Therapeutics
- Redmile Group
- Regen BioPharma
- Regulus Therapeutics
- Rejuvenation Technologies
- Remeditex Ventures
- RENAP
- Rev1 Ventures
- Ridgeback Capital
- Riesner Verwaltungs
- Rivas Capital
- RNACure
- RNAimmune
- Roche
- Roivant Sciences
- RTW Investments
- S2G Ventures
- Samsara BioCapital
- Sangel Capital
- Sanofi
- Sequoia Capital
- Shinhan Capital
- Silenseed
- Silicon Valley Bank
- Sirnaomics
- Skyline Ventures
- Smilegate Investment
- SoftBank Vision Fund
- Soluventis
- SR One
- ST Pharm
- Stemirna Therapeutics
- Suzhou Ribo Life Science
- SV Life Sciences
- Symbiosis International (Deemed University)
- Takeda Pharmaceuticals
- Tao Capital Partners
- Tavistock Life Sciences
- Temasek
- Terra Magnum Capital Partners
- The Column Group
- TransCode Therapeutics
- Trinitas Capital Management
- Turn Biotechnologies
- Ultragenyx
- Venrock Healthcare Capital Partners
- Versant Ventures
- Vida Ventures
- Viking Global Investors
- Vir Biotechnology
- Viridian Therapeutics
- VitaDAO
- Vivo Capital
- Walvax Biotechnology
- Wellington Management
- Western Australian Institute for Medical Research (WAIMR)
- Ziphius Vaccines
Methodology
LOADING...
